Immunochemistry Services Now Available in Kansas
PRA, a leading clinical research organization, today announced that in addition to offering full-service bioanalytical capabilities in its Assen, The Netherlands, laboratory, it will add immunochemistry services in its Lenexa, Kan., laboratory. PRA is now the only company in the world with full-service bioanalytical capabilities near its clinics to support rapid results from Phase I clinical studies in both the U.S. and Europe, facilitating complex and adaptive study design.
“By expanding our services to large molecule bioanalysis, we can now support all types of clinical trials,” said Chad Briscoe, Ph.D, PRA executive director, Science & Innovations, Bioanalytical Laboratories. “It is an important addition to our services because the contribution of large molecules in drug research and the development of biosimilars have increased rapidly over the past few years.”
PRA's Early Development Services group is committed to the highest standards of clinical excellence and scientific expertise. With more than 1,000 staff, 500 beds, eight clinics and two laboratories, it is the most comprehensive early development organization in the world. From its state-of-the-art facilities, the group provides the pharmaceutical and biotech industries with the unique scientific environment required for complex compound development and testing in both healthy volunteers and patients. In addition, PRA’s harmonized laboratory facilities in The Netherlands and the U.S. are situated close to the clinical facilities and are configured to fully support all clinical study requirements.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.